NeuroSense Therapeutics (NASDAQ:NRSN) Issues Earnings Results

NeuroSense Therapeutics (NASDAQ:NRSN) released its earnings results on Wednesday. The company reported ($0.11) earnings per share (EPS) for the quarter, Zacks reports.

NeuroSense Therapeutics Trading Up 3.2 %

Shares of NASDAQ NRSN traded up $0.04 during midday trading on Wednesday, reaching $1.13. The company’s stock had a trading volume of 401,737 shares, compared to its average volume of 264,754. NeuroSense Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.33. The stock has a 50 day simple moving average of $1.12 and a 200-day simple moving average of $1.03. The stock has a market capitalization of $15.38 million, a price-to-earnings ratio of -1.27 and a beta of 1.38.

Analyst Upgrades and Downgrades

Separately, Maxim Group reiterated a “hold” rating on shares of NeuroSense Therapeutics in a report on Monday.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.